Pure Global AI
NCT06352892Not yet recruiting

A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight

A Phase 1, Open-label, Randomized, Parallel-group, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of AMG 133 Administered Subcutaneously in Chinese Subjects With Obesity or Overweight
AmgenPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Obesity
Drug/Device/Intervention
AMG 133
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Amgen
Timeline & enrollment
Phase
Phase 1
Start date
Apr 24, 2024
End date
Sep 03, 2024
Enrollment
20 participants
Primary outcome

Maximum Observed Plasma Concentration (Cmax) of AMG 133,Area Under the Plasma Concentration-time Curve (AUC) from Time Zero to the Last Quantifiable Concentration (AUClast) of AMG 133,AUC from Time Zero Extrapolated to Infinity (AUCinf) of AMG 133

Summary

The main objective of the study is to assess the pharmacokinetics (PK) of AMG 133 after a
 single subcutaneous (SC) administration in overweight or obese Chinese participants.

ICD-10 classifications
ObesityOther obesityObesity, unspecifiedObesity due to excess caloriesObesity and other hyperalimentation
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06352892
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06352892 through Pure Global AI's free database. This Phase 1 trial is sponsored by Amgen and is currently Not yet recruiting. The study focuses on Obesity. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.